G Jackson

Summary

Country: UK

Publications

  1. doi request reprint Erectile dysfunction and coronary disease: evaluating the link
    Graham Jackson
    Guy s and St Thomas Hospitals NHS Trust, United Kingdom
    Maturitas 72:263-4. 2012
  2. doi request reprint Assessing the problem of counterfeit medications in the United Kingdom
    G Jackson
    Cardiac Department, St Thomas Hospital, London, UK
    Int J Clin Pract 66:241-50. 2012
  3. doi request reprint Prevention of cardiovascular disease by the early identification of erectile dysfunction
    G Jackson
    Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
    Int J Impot Res 20:S9-14. 2008
  4. doi request reprint Erectile dysfunction and silent coronary artery disease: abnormal computed tomography coronary angiogram in the presence of normal exercise ECGs
    G Jackson
    Cardiothoracic Centre, Guy s and St Thomas NHS Hospital Trust, St Thomas Hospital, London, UK
    Int J Clin Pract 62:973-6. 2008
  5. ncbi request reprint The importance of risk factor reduction in erectile dysfunction
    Graham Jackson
    Cardiothoracic Centre, 6th Floor, East Wing, St Thomas Hospital, Lambeth Palace Road, London, SE1 7EH, United Kingdom
    Curr Urol Rep 8:463-6. 2007
  6. ncbi request reprint Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective
    Graham Jackson
    St Thomas Hospital, London, United Kingdom
    Urology 68:47-60. 2006
  7. ncbi request reprint Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events
    Graham Jackson
    Guy s and St Thomas Hospital, London, UK
    J Sex Med 1:161-7. 2004
  8. ncbi request reprint Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction
    Graham Jackson
    St Thomas Hospital, London, UK
    J Sex Med 2:407-14. 2005
  9. ncbi request reprint Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction
    Graham Jackson
    Guy s and St Thomas Hospital Cardiothoracic Centre, London, United Kingdom
    J Sex Med 2:513-6. 2005
  10. ncbi request reprint The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine
    Graham Jackson
    Cardiothoracic Center, St Thomas Hospital, London, UK
    J Sex Med 3:28-36; discussion 36. 2006

Detail Information

Publications101 found, 100 shown here

  1. doi request reprint Erectile dysfunction and coronary disease: evaluating the link
    Graham Jackson
    Guy s and St Thomas Hospitals NHS Trust, United Kingdom
    Maturitas 72:263-4. 2012
    ..Its treatment is often successful, maintaining quality of life in the middle aged and elderly. ED should always be queried as part of the ongoing health care worker and patient relationship - its early detection may prevent early death...
  2. doi request reprint Assessing the problem of counterfeit medications in the United Kingdom
    G Jackson
    Cardiac Department, St Thomas Hospital, London, UK
    Int J Clin Pract 66:241-50. 2012
    ....
  3. doi request reprint Prevention of cardiovascular disease by the early identification of erectile dysfunction
    G Jackson
    Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
    Int J Impot Res 20:S9-14. 2008
    ..This article discusses the rationale for the link between ED and CAD, with reference to endothelial dysfunction, and the role of ED as an important means of identifying men at risk of vascular disease...
  4. doi request reprint Erectile dysfunction and silent coronary artery disease: abnormal computed tomography coronary angiogram in the presence of normal exercise ECGs
    G Jackson
    Cardiothoracic Centre, Guy s and St Thomas NHS Hospital Trust, St Thomas Hospital, London, UK
    Int J Clin Pract 62:973-6. 2008
    ..Exercise electrocardiography may identify flow-limiting CAD but cardiac computed tomography (CT) may identify early non-calcified plaque disease potentially vulnerable to rupture precipitating an acute event...
  5. ncbi request reprint The importance of risk factor reduction in erectile dysfunction
    Graham Jackson
    Cardiothoracic Centre, 6th Floor, East Wing, St Thomas Hospital, Lambeth Palace Road, London, SE1 7EH, United Kingdom
    Curr Urol Rep 8:463-6. 2007
    ..Though phosphodiesterase type 5 inhibitors are highly effective in treating ED, lifestyle advice and aggressive risk reduction remain fundamental to the overall vascular good health of the individual...
  6. ncbi request reprint Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective
    Graham Jackson
    St Thomas Hospital, London, United Kingdom
    Urology 68:47-60. 2006
    ..Management recommendations based on cardiovascular risk, from the Second Princeton Consensus Conference, are presented...
  7. ncbi request reprint Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events
    Graham Jackson
    Guy s and St Thomas Hospital, London, UK
    J Sex Med 1:161-7. 2004
    ..Cardiovascular disease and erectile dysfunction (ED) share similar risk factors and often occur concomitantly. Therefore, men with ED may be at increased risk for cardiovascular adverse events...
  8. ncbi request reprint Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction
    Graham Jackson
    St Thomas Hospital, London, UK
    J Sex Med 2:407-14. 2005
    ..Mild hemodynamic effects have been reported with sildenafil citrate therapy...
  9. ncbi request reprint Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction
    Graham Jackson
    Guy s and St Thomas Hospital Cardiothoracic Centre, London, United Kingdom
    J Sex Med 2:513-6. 2005
    ..Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction...
  10. ncbi request reprint The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine
    Graham Jackson
    Cardiothoracic Center, St Thomas Hospital, London, UK
    J Sex Med 3:28-36; discussion 36. 2006
    ..The first Princeton Consensus Conference (Princeton I) in 1999 developed guidelines for safe management of cardiac patients regarding sexual activity and the treatment of ED...
  11. ncbi request reprint Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors
    Graham Jackson
    Cardiothoracic Centre, St Thomas Hospital, London, UK
    Am J Cardiol 96:32M-36M. 2005
    ....
  12. ncbi request reprint Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection
    Graham Jackson
    St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Drugs 64:1533-45. 2004
    ..Addressing ED in patients with cardiovascular disease can lead to a substantial improvement in quality of life and success is not difficult to achieve...
  13. pmc Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
    G Jackson
    Cardiac Department, St Thomas Hospital, London, UK
    Int J Clin Pract 64:497-504. 2010
    ..The worldwide nature of the counterfeit problem requires proper coordination between countries to ensure adequate enforcement. Locally, physicians who treat ED need to inform patients of the dangers of ordering PDE5is via the Internet...
  14. doi request reprint Cardiovascular aspects of sexual medicine
    Graham Jackson
    Guy s and St Thomas Hospitals NHS Trust, Cardiology, London, UK
    J Sex Med 7:1608-26. 2010
    ..Erectile dysfunction (ED) is common and considered to be predominantly of vascular origin...
  15. doi request reprint Gender differences in cardiovascular disease prevention
    Graham Jackson
    Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
    Menopause Int 14:13-7. 2008
    ....
  16. doi request reprint Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus
    G Jackson
    Cardiology, London Bridge Hospital, London, UK
    Int J Clin Pract 64:848-57. 2010
    ..Review of cardiovascular status and response to ED therapy should be performed at regular intervals (Level 1, Grade A)...
  17. ncbi request reprint Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance
    H A Walker
    Cardiothoracic Centre, St. Thomas' Hospital, London, United Kingdom
    J Am Coll Cardiol 38:499-505. 2001
    ....
  18. ncbi request reprint A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement--update 2002
    G Jackson
    Cardiothoracic Centre, St Thomas Hospital, London, UK
    Int J Clin Pract 56:663-71. 2002
    ..The pro-active management of ED in the cardiovascular patient provides an ideal and effective opportunity to address other cardiovascular risk factors and improve treatment outcomes...
  19. ncbi request reprint Cardiovascular risk factors determine erectile and arterial function response to sildenafil
    Hemant Solomon
    Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, London, United Kingdom
    Am J Hypertens 19:915-9. 2006
    ..Sildenafil is effective in treatment of erectile dysfunction but shows variable results. This study investigated the relationship of cardiovascular risk factors to acute and chronic responses to sildenafil...
  20. ncbi request reprint Is erectile dysfunction a marker for cardiovascular disease?
    M Kirby
    Department of Cardiology, Guy s Hospital, London, UK
    Int J Clin Pract 55:614-8. 2001
    ..Unrestricted NHS availability of ED treatments such as sildenafil could facilitate greater achievement of National Service Framework targets for coronary heart disease...
  21. ncbi request reprint Viagra on the internet: unsafe sexual practice
    H Solomon
    Department of Cardiology, Guy s and St Thomas Hospital, London, UK
    Int J Clin Pract 56:403-4. 2002
    ..In this case report we highlight that ED itself is a risk factor for occult CHD and illustrate the need for careful medical assessment and adherence to published guidelines for the management of ED...
  22. ncbi request reprint Past, present, and future: a 7-year update of Viagra (sildenafil citrate)
    G Jackson
    Guys and St Thomas Hospital Trust, London, UK
    Int J Clin Pract 59:680-91. 2005
    ..Special emphasis is placed on the impact of sildenafil on our understanding of sexual health and on the extensive safety and efficacy data that have been amassed from numerous clinical trials...
  23. ncbi request reprint Erectile dysfunction: cardiovascular risk and the role of the cardiologist
    H Solomon
    Department of Cardiology, St Thomas Hospital, London, UK
    Int J Clin Pract 57:96-9. 2003
    ..ED is associated with a high incidence of occult cardiovascular disease. We suggest that cardiologists can significantly contribute to the management of ED...
  24. pmc Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease?
    G W Lloyd
    The Cardiothoracic Centre, St Thomas Hospital, London, UK
    Heart 84:189-92. 2000
    ..To determine whether angina in women with established coronary heart disease varies with changes in hormone concentrations during the menstrual cycle...
  25. ncbi request reprint A qualitative study investigating patients' beliefs about cardiac rehabilitation
    A F Cooper
    Cardiothoracic Centre, St Thomas Hospital, London, UK
    Clin Rehabil 19:87-96. 2005
    ..The opportunity to attend a cardiac rehabilitation course is usually offered to patients who have suffered a myocardial infarction. However, despite referral, many patients fail to attend...
  26. ncbi request reprint Sexual dysfunction and diabetes
    G Jackson
    Cardiothoracic Centre, St Thomas Hospital, London, UK
    Int J Clin Pract 58:358-62. 2004
    ..Problems with arousal, lubrication and orgasmic dysfunction occur, but the fatigue of diabetes may be influencing these complaints, and in general, psychological issues appear to predominate...
  27. ncbi request reprint Phosphodiesterase 5 inhibition: effects on the coronary vasculature
    G Jackson
    Cardiac Department, St Thomas' Hospital, London SE1 7EH, UK
    Int J Clin Pract 55:183-8. 2001
    ..Together with findings from other studies, these data suggest that PDE5 may play an important role in the regulation of coronary blood flow in the healthy and diseased heart...
  28. ncbi request reprint Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefit
    G Jackson
    Cardiothoracic Centre, St Thomas Hospital, London, UK
    Int J Clin Pract 56:397-8. 2002
    ..Sildenafil acting as a phosphodiesterase 5 inhibitor may have an important role to play in the management of PPH and we believe further study to be of importance...
  29. ncbi request reprint Smoking cessation: a consensus statement with special reference to primary care
    G Jackson
    Cardiothoracic Centre, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Int J Clin Pract 55:385-92. 2001
    ..Smoking cessation is one of the most cost-effective healthcare interventions that can be made...
  30. pmc Assessing patients' beliefs about cardiac rehabilitation as a basis for predicting attendance after acute myocardial infarction
    A F Cooper
    Cardiothoracic Centre, Guy s and St Thomas NHS Foundation Trust, London, UK
    Heart 93:53-8. 2007
    ....
  31. ncbi request reprint Factors associated with cardiac rehabilitation attendance: a systematic review of the literature
    A F Cooper
    Cardiothoracic Centre, 6th Floor, East Wing, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Clin Rehabil 16:541-52. 2002
    ..Many eligible patients fail to attend cardiac rehabilitation courses...
  32. ncbi request reprint Erectile dysfunction and statin treatment in high cardiovascular risk patients
    H Solomon
    Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, Lambeth Palace Road, London, UK
    Int J Clin Pract 60:141-5. 2006
    ..This study suggests ED following statin therapy is more likely in patients with severe endothelial dysfunction due to established cardiovascular risk factors including age, smoking and diabetes...
  33. pmc Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator
    H Solomon
    Department of Cardiology, 6th Floor, East Wing, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Heart 89:251-3. 2003
    ..Cardiovascular risk stratification is an important initial step in managing such patients. In cardiac patients considered to have low cardiovascular risk, the management of ED can be safe and effective...
  34. ncbi request reprint Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital Lambeth Palace Road, London SE1 7EH, UK
    Atherosclerosis 185:421-5. 2006
    ..Erectile dysfunction is related to penile arterial endothelial nitric oxide production. Asymmetric dimethylarginine (ADMA) and E-selectin are often considered plasma markers of endothelial function...
  35. doi request reprint Sexual response in cardiovascular disease
    Graham Jackson
    London Bridge Hospital, London, England
    J Sex Res 46:233-6. 2009
    ..As erectile dysfunction in men over 40 years of age is usually of vascular (endothelial dysfunction) origin, they should be considered "cardiovascular equivalents," and secondary prevention guidelines should be followed...
  36. doi request reprint The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician
    G Jackson
    Department of Cardiology, Guy s and St Thomas Hospitals London, London, UK
    Int J Clin Pract 67:1163-72. 2013
    ..Finally, we recommend that a question about ED be included in assessment of CVD risk in all men and be added to CVD risk assessment guidelines. ..
  37. doi request reprint Erectile dysfunction and asymptomatic coronary artery disease: frequently detected by computed tomography coronary angiography but not by exercise electrocardiography
    G Jackson
    London Bridge Hospital, London, UK Guy s and St Thomas Hospitals NHS Trust, London, UK
    Int J Clin Pract 67:1159-62. 2013
    ..This study compares multi-detector cardiac computed tomography (MDCT) with maximal treadmill exercising in men with ED and no coronary symptoms as a means of detecting coronary lesions...
  38. pmc Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis
    M Kirby
    Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, UK
    Int J Clin Pract 67:606-18. 2013
    ....
  39. ncbi request reprint Risk factor management: the cardiologist's perspective
    G Jackson
    Guy s Hospital, London, UK
    Br J Clin Pract Suppl 77:33-9. 1996
    ..The patient is a victim of poor investment in prevention, while the cardiologist is put off by a perceived lack of balance from the medical protagonists...
  40. ncbi request reprint Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents
    G Jackson
    Cardiothoracic Centre, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Int J Clin Pract 55:256-61. 2001
    ..It is suggested that combination haemodynamic and metabolic therapy is a logical new approach to patients whose angina is inadequately controlled despite optimal haemodynamic therapy...
  41. ncbi request reprint Haemodynamic and metabolic agents in the treatment of stable angina: publication review
    G Jackson
    Guy s and St Thomas Hospitals, NHS Trust, Cardiothoracic Centre, London, UK
    Coron Artery Dis 12:S22-4. 2001
    ..Patients who fail to respond to optimal haemodynamic and metabolic therapy should be considered for a revascularisation procedure, not random additional drug therapy...
  42. ncbi request reprint The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial
    G W Lloyd
    Guys and St Thomas Hospital Trust, Lambeth Palace Road, London SE1 7EH, UK
    Atherosclerosis 158:445-54. 2001
    ....
  43. ncbi request reprint Making PROGRESS in stable patients post stroke or transient ischaemic attack: implications for general practice
    G Jackson
    Cardiothoracic Centre, St Thomas Hospital, London, UK
    Int J Clin Pract 57:385-7. 2003
    ..g. aspirin, statins). Therapy can be initiated and monitored either from hospital outpatients or general practice or both in co-operation...
  44. ncbi request reprint Guidelines on the management of acute myeloid leukaemia in adults
    D W Milligan
    British Society for Haematology, London, UK
    Br J Haematol 135:450-74. 2006
  45. ncbi request reprint Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey
    N Salooja
    Department of Haematology, Imperial College of Science and Medicine, Hammersmith Hospital, London, UK
    Lancet 358:271-6. 2001
    ..INTERPRETATION: Pregnancy after SCT is likely to have a successful outcome. Pregnancies in allograft patients who have received total body irradiation should be treated as high risk for maternal and fetal complications...
  46. ncbi request reprint Erectile dysfunction: is there silent obstructive coronary artery disease?
    P D O'Kane
    Cardiothoracic Centre, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Int J Clin Pract 55:219-20. 2001
    ..The presence of silent co-existing myocardial ischaemia should be considered in men who present with ED, particularly when they have other cardiovascular risk factors...
  47. pmc Biologic therapies for juvenile arthritis
    N Wilkinson
    Department of Rheumatology, Great Ormond Street Hospital, London, UK
    Arch Dis Child 88:186-91. 2003
    ..However, as will also be discussed, overlap of pathways within a complex immune system makes clinical response unpredictable and raises additional ethical and administrative concerns...
  48. ncbi request reprint The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol
    H A Walker
    Cardiothoracic Centre, St Thomas' Hospital, London, UK
    Circulation 103:258-62. 2001
    ..CONCLUSIONS: Genistein causes L-arginine/NO-dependent vasodilation in forearm vasculature of human subjects with similar potency to 17beta-estradiol and potentiates endothelium-dependent vasodilation to acetylcholine...
  49. ncbi request reprint Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteine
    Peter D O'Kane
    Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, London, UK
    Atherosclerosis 196:574-9. 2008
    ..As a secondary aim, we wished to ascertain whether whole body NO biosynthesis is inversely related to plasma homocysteine (Hcy) levels...
  50. ncbi request reprint Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment
    Peter D O'Kane
    Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, London, UK
    Cardiovasc Res 59:152-9. 2003
    ..We examined the effects of aspirin on basal and beta-adrenoceptor (beta-AR)-mediated nitric oxide synthase (NOS) activity in normal platelets...
  51. ncbi request reprint PDE5 inhibitors: looking beyond ED
    Graham Jackson
    Int J Clin Pract 57:159-60. 2003
  52. ncbi request reprint Vascular risk factors and erectile dysfunction: 'sexing-up' the importance of lifestyle changes
    Graham Jackson
    Int J Clin Pract 61:1421-2. 2007
  53. ncbi request reprint The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines, new challenges
    Graham Jackson
    Int J Clin Pract 60:127. 2006
  54. ncbi request reprint Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study
    Ian Eardley
    Pyrah Department of Urology, St James University Hospital, Becket Street, Leeds, UK
    BJU Int 100:122-9. 2007
    ....
  55. ncbi request reprint Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Cardiol 97:1778-84. 2006
    ..In this clinical trial population of men with erectile dysfunction, tadalafil was not associated with an increased risk for serious cardiovascular adverse events...
  56. ncbi request reprint Sildenafil (Viagra): new data, new confidence in treating erectile dysfunction in the cardiovascular patient
    Graham Jackson
    Int J Clin Pract 56:75. 2002
  57. ncbi request reprint Time course of the interaction between tadalafil and nitrates
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Am Coll Cardiol 42:1855-60. 2003
    ..This study was designed to determine the time course of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h...
  58. ncbi request reprint Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Am J Cardiol 96:85M-93M. 2005
    ..Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended...
  59. ncbi request reprint Phosphodiesterase inhibition: erectile dysfunction is only part of the story
    Graham Jackson
    Int J Clin Pract 56:236. 2002
  60. ncbi request reprint Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Am J Cardiol 96:313-21. 2005
    ..Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended...
  61. ncbi request reprint Vardenafil--PDE5 inhibitor number 3
    Graham Jackson
    Int J Clin Pract 58:229. 2004
  62. ncbi request reprint Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference
    Raymond C Rosen
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08854, USA
    Curr Urol Rep 7:490-6. 2006
    ..Other drug interactions and the cardiovascular safety of testosterone replacement therapy are considered...
  63. ncbi request reprint Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease
    Hunter C Gillies
    Clinical Development, Pfizer Global Research and Development, Ramsgate Road, Kent CT13 9NJ, Sandwich, UK
    Int J Cardiol 86:131-41. 2002
    ..Finally, exciting reports have emerged from clinical experience with the use of phosphodiesterase type 5 inhibitors in patients with pulmonary hypertension...
  64. ncbi request reprint Letter regarding article by Gazzaruso et al, "Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated, type 2 diabetic patients"
    Graham Jackson
    Circulation 111:e18-9; author reply e18-9. 2005
  65. ncbi request reprint Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men
    Robert A Kloner
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90017, USA
    J Urol 172:1935-40. 2004
    ..We examined the hemodynamic interactions of tadalafil with the alpha-blockers doxazosin and tamsulosin...
  66. ncbi request reprint Erectile dysfunction: a marker of silent coronary artery disease
    Graham Jackson
    Eur Heart J 27:2613-4. 2006
  67. ncbi request reprint Should erectile dysfunction be treated as secondary prevention for coronary disease?
    Graham Jackson
    Int J Clin Pract 60:1335. 2006
  68. ncbi request reprint The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention
    Raymond C Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, NJ, USA
    J Sex Med 3:960-75; discussion 973-5. 2006
    ..Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals...
  69. ncbi request reprint Women and heart disease: a British Heart Foundation initiative
    Graham Jackson
    Int J Clin Pract 57:75. 2003
  70. ncbi request reprint The cardiac urologist
    Graham Jackson
    Int J Clin Pract 61:181-2. 2007
  71. ncbi request reprint Ranolazine--a nicely timed new medical therapy for stable angina
    Graham Jackson
    Int J Clin Pract 61:1063. 2007
  72. ncbi request reprint Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial
    Patrick W J C Serruys
    Interventional Cardiology, Thoraxcenter, Bd 418, Academic Hospital, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    JAMA 287:3215-22. 2002
    ....
  73. ncbi request reprint A male cardiovascular sexual health clinic
    Graham Jackson
    Int J Clin Pract 56:631. 2002
  74. doi request reprint Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets
    Peter D O'Kane
    Department of Clinical Pharmacology, Cardiovascular Division, 3 07 Franklin Wilkins Building, King s College London, 150 Stamford Street, London SE1 9NH, UK
    J Mol Cell Cardiol 45:223-9. 2008
    ..Moreover, CHD may itself be associated with decreased platelet NO biosynthesis...
  75. ncbi request reprint "Oh ... by the way ... ": doorknob syndrome
    Graham Jackson
    Int J Clin Pract 59:869. 2005
  76. ncbi request reprint Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
    Sylvia Feyler
    St James University Hospital, Leeds, UK
    Br J Haematol 139:429-33. 2007
    ..5 months. Maintenance doses >200 mg were largely unachievable and peripheral neuropathy was the main toxicity. Lower doses enabled more patients to stay on the drug for a useful period of time...
  77. ncbi request reprint Testosterone - not just a replacement therapy
    Graham Jackson
    Int J Clin Pract 60:1021-2. 2006
  78. ncbi request reprint Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
    ..Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients...
  79. ncbi request reprint Erectile dysfunction: the need to be evaluated, the right to be treated
    Hemant Solomon
    Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Am Heart J 150:620-6. 2005
    ..Specific guidelines for the management of ED in cardiac patients, produced by 2 expert panels, can also be applied to men without known cardiovascular disease...
  80. ncbi request reprint Blood pressure lowering--is degree more important than method?
    Graham Jackson
    Int J Clin Pract 59:995-7. 2005
  81. ncbi request reprint Stable angina--medical therapy gives us time to optimise management
    Graham Jackson
    Int J Clin Pract 58:107-8. 2004
  82. ncbi request reprint Believe-it then PROVE-IT
    Graham Jackson
    Int J Clin Pract 58:325-6. 2004
  83. ncbi request reprint Lipids and cardiovascular risk reduction -- new targets, new challenges
    Graham Jackson
    Int J Clin Pract 59:617-8. 2005
  84. ncbi request reprint Prevention of disease--education makes a difference in the community
    Graham Jackson
    Int J Clin Pract 59:263. 2005
  85. ncbi request reprint Safety and compliance of intravenous and oral dosing regimens
    Graham Jackson
    Oncologist 10:313-4; author reply 315-6. 2005
  86. ncbi request reprint Endothelial function and dysfunction
    Graham Jackson
    Int J Clin Pract 58:431. 2004
  87. ncbi request reprint Diabetic and hypertension guidelines updated
    Graham Jackson
    Int J Clin Pract 58:815-6. 2004
    ..No risk factor should be managed in isolation--overall risk reduction is essential. We have a job to do and must do it thoroughly--we now need a programme of early detection and that needs political will and investment...
  88. ncbi request reprint PDE 5 inhibitors and HIV risk: current concepts and controversies
    Graham Jackson
    Int J Clin Pract 59:1247-8. 2005
  89. ncbi request reprint Giving up smoking
    Graham Jackson
    Hosp Med 65:134-5. 2004
  90. ncbi request reprint Smoking: suicide for some, manslaughter for others--time for a ban in all public places
    Graham Jackson
    Int J Clin Pract 58:1. 2004
  91. ncbi request reprint Erectile dysfunction and vascular risk: Let's get it right
    Graham Jackson
    Eur Urol 50:660-1. 2006
  92. ncbi request reprint Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis
    Graham Jackson
    Int J Clin Pract 60:891-2. 2006
  93. ncbi request reprint Erectile dysfunction, like diabetes, should be considered a 'cardiovascular equivalent'
    Graham Jackson
    Int J Clin Pract 59:507. 2005
  94. ncbi request reprint Sexual medicine society of North America
    Graham Jackson
    Int J Clin Pract 60:759-60. 2006
  95. ncbi request reprint The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism
    Graham Jackson
    Eur Urol 50:426-7. 2006
  96. ncbi request reprint Primary angioplasty in acute myocardial infarction - the preferred option, but time is of the essence
    Graham Jackson
    Int J Clin Pract 60:379. 2006
  97. ncbi request reprint Denial
    Graham Jackson
    Int J Clin Pract 60:253. 2006
  98. ncbi request reprint Hypertension: treating the patient as well as the blood pressure
    Graham Jackson
    Int J Clin Pract 57:357. 2003
  99. ncbi request reprint Smoking politics
    Graham Jackson
    Int J Clin Pract 58:649. 2004
  100. ncbi request reprint Pharmacotherapy for erectile dysfunction
    Harin Padma-Nathan
    J Sex Med 1:128-40. 2004
    ..Advances in understanding of the biochemistry and physiology of penile erection have led to breakthroughs in pharmacotherapy of erectile dysfunction...
  101. ncbi request reprint Erectile dysfunction: a management algorithm
    Graham Jackson
    Int J Clin Pract 58:733-4. 2004